Provectus Pharmaceuticals, Inc. (PVCT.OB) Treats First Patient with Topical PH-10 at Mount Sinai School of Medicine
Provectus announced today that it has begun treating its first patient and is recruiting patients for the Phase 2 clinical trial of topical PH-10, which is designed to treat psoriasis. The study will assess the effectiveness of topically applied PH-10 in twenty-five participants. The medication will be administered twice a week for up to twelve weeks. The entire study is taking place at the Mount Sinai School of Medicine in New York and is anticipated to take nine months to complete. Craig Dees, Ph.D., CEO of Provectus, stated, “We are pleased to offer patients with moderate to severe psoriasis the…